Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

eas of pediatric infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at www.medimmune.com.

Forward Looking Statements

This announcement may contain, in addition to historical information, certain forward-looking statements regarding motavizumab, an investigational MAb, which involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune's filings with the U.S. Securities and Exchange Commission. The company is developing motavizumab for potential future marketing. There can be no assurance that such development efforts will succeed, that motavizumab will receive required regulatory approval or that, even if such regulatory approval is received, that motavizumab would ultimately achieve commercial success.

Notice to Investors and Stockholders of MedImmune

This release is neither an offer to purchase nor a solicitation of an offer to sell shares of MedImmune. MedImmune stockholders are urged to read the relevant tender offer documents from AstraZeneca PLC which have been filed on May 3, 2007 because they will contain important information that stockholders should consider before making any decision regarding tendering their shares. AstraZeneca has filed tender offer materials with the U.S. Securities and Exchange Commission, and MedImmune has also filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement contain important informat
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/30/2014)... , Oct. 30, 2014  Zimmer Holdings, Inc. ... announced the future executive leadership team and organizational structure ... Biomet transaction.  Zimmer also announced that the combined organization ... will be named Zimmer Biomet, with the new brand ... the closing of the merger.  The future leadership team ...
(Date:10/30/2014)... NEW YORK , Oct. 30, 2014  The ... United States is growing steadily, thanks to ... years, as a result of the economic downturn, retail ... was a year of opportunities, as the number of ... market researcher,s report, Retail Clinics Market Overview and ...
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
Breaking Medicine Technology:Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3China Biologic to Report Third Quarter 2014 Financial Results 2
... REGN ) today announced that the Company ... agreement (Agreement) with Genentech, Inc., a member of the ... U.S. ophthalmic sales of EYLEA™ (aflibercept) Injection. ... relating to VEGF receptor proteins, known as the Davis-Smyth ...
... testing, the gold standard in hypothyroid diagnosis, may be ... article titled Hormone Replacement Therapy in the ... for the Future. Estrogen, Progesterone, Testosterone, and Thyroid Hormone ... independently written and published, is a broad study of ...
Cached Medicine Technology:Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection 2Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection 3Studies Show That TSH Is Unreliable in the Diagnosis of Hypothyroidism According to Article Contributed by Kent Holtorf, M.D. in Clinical Geriatrics 2
(Date:10/30/2014)... cancer care respects the fact that a patient,s ... requires treatment. Over a third of cancer patients ... of their conditions. And, increasingly, care providers are ... patients navigate mental health challenges. A University of ... journal Psycho-Oncology asks an important question: ...
(Date:10/29/2014)... The development of minimally and even non-invasive technologies is ... for instance, to carry out a range of operative ... scalpel, leaving only tiny scars as a result. Similar ... active agents to patients – instead of using injections ... be possible to supply them via a plaster which ...
(Date:10/29/2014)... certain prostate cancer medications are linked with an increased ... congestive heart failure or prior heart attacks. Published in ... and patients weigh the benefits and risks of the ... levels of male hormones in the body to prevent ... treatment for prostate cancer. Despite its anticancer effects, ADT ...
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
(Date:10/28/2014)... NY (October 27, 2014)—Although oral hormonal therapy is ... women with hormone receptor–positive tumors, about one-half of ... A study by Columbia University Medical Center (CUMC) ... aromatase inhibitors (the most common type of hormone ... brand-name counterparts, increased treatment adherence by 50 percent. ...
Breaking Medicine News(10 mins):Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2Health News:Gentle caffeine boost for premature babies 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2Health News:New insights into the development of ciliopathies 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3
... , MONDAY, Jan. 17 (HealthDay News) -- Patients at high ... detect the deadly skin cancer at an early stage, new ... some people from having a doctor examine their skin for ... Archives of Dermatology . People at high risk for ...
... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... flares of multiple sclerosis (MS), but does not help ... guidelines say. Plasma exchange, or plasmapheresis, is also ... chronic inflammatory demyelinating polyneuropathy and it may be considered ...
... poor can prevent young children from reaching their full genetic potential ... University of Texas at Austin looked at 750 sets of twins ... and 2 years. During the tests the children were asked to ... placing three cubes in a cup, and matching pictures. At ...
... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... called calcium channel blockers face an increased risk of ... shock if they take certain antibiotics, Canadian researchers warn. ... to patients taking calcium channel blockers, can increase the ...
... -- Among middle-school students, friendships can make the difference ... Students whose friends are socially active in positive ways ... badly get lower grades, according to the results of ... also staying away from deviant peers was associated with ...
... surgery remains significantly different when compared to the patient,s opposite ... a study that updated prior findings, researchers used X-rays providing ... relation to the shoulder blade, to compared motion in the ... tendon tears and no symptoms in their other shoulders. An ...
Cached Medicine News:Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 2Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 3Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 2Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 3Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 2Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 3Health News:Friends a Big Influence on Grades in Middle School: Study 2Health News:Henry Ford Hospital study: Shoulder function not fully restored after surgery 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers. Polyethylene cover....
Medicine Products: